Global Cancer Gene Therapy Market

Cancer Gene Therapy Market Size, Share, Growth Analysis, By Type (Ex-Vivo, In-Vivo), By Therapy (Oncolytic Virotherapy, Gene-Induced Immunotherapy), By Product (Viral Vectors, Non-Viral Vectors), By End Use, By Region - Industry Forecast 2026-2033

Report ID: SQMIG35G2180 | Region: Global | Published Date: December, 2025
Pages: 157 |Tables: 95 |Figures: 76

To request a free sample copy of this report, please complete the form below.

Our Clients

  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt
  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt

    • FAQs

    Global Cancer Gene Therapy Market size was valued at USD 4.25 Billion in 2024 and is poised to grow from USD 5.16 Billion in 2025 to USD 24.34 Billion by 2033, growing at a CAGR of 21.4% during the forecast period (2026–2033). 

    Cancer gene therapy providers should be targeting regions and countries with high incidence of cancer to maximize their business scope. Collaborating and partnering with healthcare providers could also help market players increase their revenue generation potential. Investing in research and development is highly essential for cancer gene therapy types of cancer gene therapy companies in the long run.   'Novartis AG (Switzerland) ', 'Gilead Sciences, Inc. (USA) ', 'Bristol Myers Squibb Company (USA) ', 'CRISPR Therapeutics (Switzerland) ', 'Amgen Inc. (USA) ', 'Merck KGaA (Germany) ', 'Intellia Therapeutics, Inc. (USA) ', 'Adaptimmune Therapeutics (UK) ', 'Autolus Therapeutics (UK) ', 'Sangamo Therapeutics, Inc. (USA) ', 'Vertex Pharmaceuticals (USA) ', 'Abeona Therapeutics Inc. (USA) ', 'Johnson & Johnson (USA) ', 'Pfizer Inc. (USA) ', 'AstraZeneca (UK) ', 'Takeda Pharmaceutical Company Limited (Japan)'

    Genetic engineering and genome mapping technologies have a come a long way owing to high investments in gene research initiatives. These advancements from the gene world are now being integrated with oncology research to create novel cancer gene therapies thereby driving market growth as well. 

    Demand for Combination Therapies: Growing number of cancer patients are opting for combination therapies to improve their chances of survival and get better treatment. Cancer gene therapy providers can focus on the development of new combination therapies to maximize their business scope in the long run.

    Lucrative environment offered by public and private institutions in the North American region to advance oncology research is what allows this region to hold a high market share. The United States is projected to remain the top market in this region owing to quick adoption of novel healthcare treatments and presence of a developed healthcare infrastructure. Canada is also an opportune market for cancer gene therapy companies in this region.

    Related Reports

    Gene Therapy Market
    Buy Now GET FREE SAMPLE
    Cancer Biological Therapy Market
    Buy Now GET FREE SAMPLE
    Cancer Therapeutics Market
    Buy Now GET FREE SAMPLE
    Breast Cancer Therapeutics Market
    Buy Now GET FREE SAMPLE
    Lung Cancer Therapeutics Market
    Buy Now GET FREE SAMPLE
    Pet Cancer Therapeutics Market
    Buy Now GET FREE SAMPLE
    Gene Editing Market
    Buy Now GET FREE SAMPLE
    Colorectal Cancer Therapeutics Market
    Buy Now GET FREE SAMPLE

    Feedback From Our Clients

    Global Cancer Gene Therapy Market

    Report ID: SQMIG35G2180

    $5,300
    BUY NOW